- Report
- February 2021
- 360 Pages
United States
From €2320EUR$2,400USD£1,993GBP
- Report
- August 2020
Global
From €5114EUR$5,290USD£4,393GBP
- Report
- February 2019
- 105 Pages
Global
From €1247EUR$1,290USD£1,071GBP
- Report
- January 2022
- 110 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- June 2019
- 16 Pages
Global
€9668EUR$10,000USD£8,304GBP
- Report
- June 2019
- 21 Pages
Global
€9668EUR$10,000USD£8,304GBP
- Report
- June 2019
- 18 Pages
Global
€9668EUR$10,000USD£8,304GBP
- Report
- June 2019
- 26 Pages
Global
€9668EUR$10,000USD£8,304GBP
Darunavir is a protease inhibitor used to treat immune disorders, such as HIV and AIDS. It is used in combination with other antiretroviral drugs to reduce the amount of HIV in the body and to prevent the virus from replicating. Darunavir is also used to treat hepatitis C virus (HCV) infection. It works by blocking the action of the HCV protease enzyme, which is necessary for the virus to replicate. Darunavir is available in tablet and oral suspension forms.
Darunavir is a widely used drug in the treatment of immune disorders. It is generally well tolerated and has few side effects. It is also effective in reducing the risk of HIV transmission. Darunavir is available in generic form, as well as under the brand name Prezista.
The Darunavir market is highly competitive, with many companies offering generic and branded versions of the drug. Some of the major players in the market include AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, and Pfizer. Show Less Read more
